Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRP + atorvastatin is a combination therapy where atorvastatin (1.2%) is delivered subgingivally as an adjunct to scaling and root planing (SRP) for the treatment of periodontal intrabony defects. The search results indicate that this combination has been studied for treating intrabony defects (IBDs) in periodontal disease, with atorvastatin being used as a locally delivered adjunct to the standard SRP procedure. Atorvastatin is primarily known as a lipid-lowering medication that inhibits 3-hydroxy-2-methyl-glutaryl coenzyme A (HMG-CoA) reductase. However, it also demonstrates pleiotropic effects including anti-inflammatory properties and bone stimulation capabilities, which make it beneficial in periodontal treatment[4]. When used in this dental application, atorvastatin is typically formulated as a 1.2% gel that is applied locally to the periodontal defect after SRP is performed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRP + atorvastatin.